| |
| COURSE LISTING |
 |
 Back to AVAILABLE COURSES
|
| |
| DISCLOSURES |
|
Accreditation/Disclosures |
| |
| INSTRUCTIONS |
|
|
This course is a companion to prev cardiol. 2008;11:168–171 It requires that you read this material before answering test questions.
You must be signed in to download the companion material or participate in the CME activity.
|
| |
| INSTANT CME |
|
| Courses bearing the INSTANT CME icon offer instant CME certificate download as soon as you complete the course! |
|
| |
|
| |
| |
| |
|
|
|
|
| COURSE SUMMARY |
|
|
| |
|
|
|
|
|
Varenicline and Its Role in Smoking Cessation
Faculty: Shailendra Kapoor, MD |
| |
|
|
|
This article was published in the Summer 2008 issue of Preventive Cardiology. Full text available HERE.
Abstract:
Varenicline is a partial agonist of a4ß2 nicotinic receptors. It was recently approved for smoking cessation in the United States. It is administered at a dosage of 0.5 mg once a day for an initial period of 3 days followed by 0.5 mg twice a day for the next 4 days. Following this, the drug is administered at a dosage of 1.0 mg twice a day. The total duration of therapy is 12 weeks. Common adverse effects include nausea, headache, and insomnia. Recent studies show that varenicline is almost twice as effective as bupropion SR in smoking cessation. Given the increased risk of cardiovascular morbidity secondary to smoking, especially in the elderly, varenicline is a major therapeutic tool in the fight against smoking. (prev cardiol. 2008;11:168–171) ©2008 Le Jacq
|
| |
|
| Est. Completion Time: 60 minutes |
|
|
| |
|
|
This CME activity has expired.
You may still access available content and post-tests. You will NOT be able to 'Hand In' this CME activity for credit. |
| |
|
Track Description |
|
|
Est. Compl. Time |
|
|
|
REVIEW PAPER - Shailendra Kapoor, MD
Varenicline and Its Role in Smoking Cessation
|
|
|
60
minutes |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
